The Neuronal Retromer Can Regulate Both Neuronal and Microglial Phenotypes of Alzheimer’s Disease

Scientists showed that the neuronal retromer could regulate Alzheimer’s disease (AD)-associated pathologies in two of AD’s principal cell types, which strengthened the link, and clarified the mechanism, between endosomal trafficking and late-onset sporadic AD.
[Cell Reports]
[zotpress userid=” items=’45XWATNZ’ style=’apa’ cite=’yes’]
Full ArticleGraphical Abstract
Bookmark

No account yet? Register

Share

Recent Investigations on Neurotransmitters’ Role in Acute White Matter Injury of Perinatal Glia and Pharmacotherapies—Glia Dynamics in Stem Cell Therapy

The authors discuss multiple pathophysiological aspects of white matter injury along with glial dynamics, and the pharmacotherapies including recent insights into the application of MSCs as therapeutic modality in treating white matter injury.
[Molecular Neurobiology]
[zotpress userid=” items=’45XWATNZ’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Transcription Elongation Machinery Is a Druggable Dependency and Potentiates Immunotherapy in Glioblastoma Stem Cells

Researchers interrogated gene expression and whole-genome CRISPR/Cas9 screening in a large panel of patient-derived glioblastoma (GBM) stem cells (GSCs), differentiated GBM cells, and neural stem cells to identify master regulators of GSC stemness.
[Cancer Discovery]
[zotpress userid=” items=’45XWATNZ’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

POLE2 Facilitates the Malignant Phenotypes of Glioblastoma through Promoting AURKA-Mediated Stabilization of FOXM1

The authors revealed crucial roles and a novel mechanism of poly ε-B subunit (POLE2) involved in glioblastoma (GBM) through Aurora kinase A (AURKA)-mediated stability of forkhead transcription factor (FOXM1) and may provide the theoretical basis of molecular therapy for GBM.
[Cell Death & Disease]
[zotpress userid=” items=’45XWATNZ’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

NEK2 Enhances Malignancies of Glioblastoma via NIK/NF-κB Pathway

Scientists found that NEK2 knockdown attenuated cell proliferation, migration, invasion, and tumorigenesis of glioblastoma (GBM) while NEK2 overexpression promoted the GBM progression.
[Cell Death & Disease]
[zotpress userid=” items=’45XWATNZ’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Single-Cell Transcriptomics of Human iPSC Differentiation Dynamics Reveal a Core Molecular Network of Parkinson’s Disease

Researchers investigated Parkinson’s disease (PD)’s mechanism using dopaminergic neurons differentiated from human iPSCs carrying the ILE368ASN mutation within the PINK1 gene, which is strongly associated with PD.
[Communications Biology]
[zotpress userid=’7992332′ items=’EEEEEEEE’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Stretchable Mesh Nanoelectronics for Three-Dimensional Single-Cell Chronic Electrophysiology from Developing Brain Organoids

The authors reported a cyborg brain organoid platform, in which “tissue-like” stretchable mesh nanoelectronics are designed to match the mechanical properties of brain organoids and to be folded by the organogenetic process of progenitor or stem cells, distributing stretchable electrode arrays across the 3D organoids.
[Advanced Materials]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Vaxxinity Announces First Parkinson’s Disease Patient Dosed in Part B of Phase I Clinical Trial of UB-312

Vaxxinity, Inc. announced that the first patient with Parkinson’s disease has been dosed with UB-312 in Part B of a double-blinded, placebo-controlled Phase I clinical trial, following completion of Part A of the Phase I trial in healthy volunteers.
[Vaxxinity, Inc.]
[zotpress userid=” items=’nan’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

PharmaTher Announces FDA Approval of Investigational New Drug (IND) Application for Ketamine to Treat ALS

PharmaTher Holdings Ltd. announced that the US FDA has accepted an investigator-initiated IND application to proceed with a Phase II clinical trial evaluating ketamine in the treatment of Amyotrophic Lateral Sclerosis (ALS).
[PharmaTher Holdings Ltd.]
[zotpress userid=” items=’nan’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

TMEM158 Promotes the Proliferation and Migration of Glioma Cells via STAT3 Signaling in Glioblastomas

Researchers found that TMEM158 expression in human glioma cells in the tumor core was significantly higher than that in noncancerous cells at the tumor edge using bioinformatics analysis.
[Cancer Gene Therapy]
[zotpress userid=” items=’45XWATNZ’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

SMURF2 Phosphorylation at Thr249 Modifies Glioma Stemness and Tumorigenicity by Regulating TGF-β Receptor Stability

Researchers demonstrated that SMAD specific E3 ubiquitin protein ligase 2 (SMURF2)Thr249 phosphorylation played an essential role in maintaining glioma stem cell (GSC) stemness and tumorigenicity. SMURF2 silencing augmented the self-renewal potential and tumorigenicity of patient-derived GSCs.
[Communications Biology]
[zotpress userid=” items=’45XWATNZ’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share
Share